Page last updated: 2024-09-04

perifosine and Adenocarcinoma Of Kidney

perifosine has been researched along with Adenocarcinoma Of Kidney in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chinn, DC; Gandara, DR; Holland, WS; Lara, PN; Mack, PC; Pietri, JE; Tepper, CG	1
Cho, DC; Figlin, RA; Flaherty, KT; Hutson, TE; Michaelson, MD; Puzanov, I; Richards, P; Samlowski, W; Somer, B; Sosman, JA; Sportelli, P; Vogelzang, NJ	1
Cho, DC; Srivastava, N	1

Reviews

1 review(s) available for perifosine and Adenocarcinoma Of Kidney

Article	Year
Perifosine in renal cell carcinoma. Expert opinion on investigational drugs, 2013, Volume: 22, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Molecular Structure; Phosphorylcholine; Randomized Controlled Trials as Topic	2013

Trials

1 trial(s) available for perifosine and Adenocarcinoma Of Kidney

Article	Year
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer, 2012, Dec-15, Volume: 118, Issue:24 Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Phosphorylcholine; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Salvage Therapy; Survival Rate; Vascular Endothelial Growth Factor A	2012

Article

Year

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.

Cancer, 2012, Dec-15, Volume: 118, Issue:24

Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Phosphorylcholine; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Salvage Therapy; Survival Rate; Vascular Endothelial Growth Factor A

2012

Other Studies

1 other study(ies) available for perifosine and Adenocarcinoma Of Kidney

Article	Year
Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Interleukin-8; Kidney Neoplasms; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases	2012

Article

Year

Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.

Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:1

Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Interleukin-8; Kidney Neoplasms; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases

2012